Pulmonary Hypertension (cont.)
George Schiffman, MD, FCCP
Dr. Schiffman received his B.S. degree with High Honors in biology from Hobart College in 1976. He then moved to Chicago where he studied biochemistry at the University of Illinois, Chicago Circle. He attended Rush Medical College where he received his M.D. degree in 1982 and was elected to the Alpha Omega Alpha Medical Honor Society. He completed his Internal Medicine internship and residency at the University of California, Irvine.
Siamak N. Nabili, MD, MPH
Dr. Nabili received his undergraduate degree from the University of California, San Diego (UCSD), majoring in chemistry and biochemistry. He then completed his graduate degree at the University of California, Los Angeles (UCLA). His graduate training included a specialized fellowship in public health where his research focused on environmental health and health-care delivery and management.
William C. Shiel Jr., MD, FACP, FACR
Dr. Shiel received a Bachelor of Science degree with honors from the University of Notre Dame. There he was involved in research in radiation biology and received the Huisking Scholarship. After graduating from St. Louis University School of Medicine, he completed his Internal Medicine residency and Rheumatology fellowship at the University of California, Irvine. He is board-certified in Internal Medicine and Rheumatology.
In this Article
- What are pulmonary arteries?
- What is pulmonary hypertension?
- What are primary and secondary pulmonary hypertension?
- What causes pulmonary hypertension?
- What causes primary pulmonary hypertension?
- How common is pulmonary hypertension?
- What are the signs and symptoms of pulmonary hypertension?
- How is pulmonary hypertension diagnosed?
- What is the treatment for pulmonary hypertension?
- What is the life expectancy for pulmonary hypertension?
- Find a local Cardiologist in your town
What is the life expectancy for pulmonary hypertension?
Generally, the prognosis of pulmonary varies depending on the underlying condition that is causing it. For idiopathic or familial pulmonary hypertension, the overall prognosis depends on the severity and whether treatment was instituted. The statistics show a survival of about 3 years in idiopathic pulmonary hypertension without any therapy. Some of the other factors may indicate even poorer prognosis which include severe symptoms, age of onset greater than 45 years, evidence of right sided heart failure, and failure to respond to treatment. For patients with idiopathic pulmonary hypertension who get started on treatment and respond to it, the prognosis is better. Studies are underway to determine optimal treatment regimens.
Medically reviewed by Robert J. Bryg, MD; Board Certified Internal Medicine with subspecialty in Cardiovascular Disease
Fauci, Anthony S., et al. Harrison's Principles of Internal Medicine. 17th ed. United States: McGraw-Hill Professional, 2010.
Pom and Kingman; Inhaled treprostinil for pulmonary arterial hypertension. CCN.2009;31(6);e1-e11.
Kiely, et al. Pulmonary hypertension;diagnosis and management. BBMJ 2013;346:f2028
Raza, T and Dilawar, M; Pulmonary Hypertension; A Comprehensive Review; Heart Views Vol. 8 No.3 Sept-Nov 2007; 90-99
Simonneau, G, Galie, N, Rubin, LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43:5S.
Simonneau, et al. Updated Clinical Classification of Pulmonary Hypertension. J Am Coll Cardiol 2009;54:43-54, doi:10.1016/j.jacc.2009.04.012
Find out what women really need.